Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity
Aim. To assess the effectiveness of a selective I1 imidazoline receptor agonist, rilmenidine, in women with Stage I arterial hypertension (AH), Type 2 diabetes mellitus (DM-2), and visceral obesity (VO), taking into account antihypertensive effects and dynamics of endothelial dysfunction (ED) bioche...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1565 |
| _version_ | 1797882816445284352 |
|---|---|
| author | E. V. Eliseeva O. V. Gaydarova O. V. Borushnova L. A. Shapkina A. M. Morozova |
| author_facet | E. V. Eliseeva O. V. Gaydarova O. V. Borushnova L. A. Shapkina A. M. Morozova |
| author_sort | E. V. Eliseeva |
| collection | DOAJ |
| description | Aim. To assess the effectiveness of a selective I1 imidazoline receptor agonist, rilmenidine, in women with Stage I arterial hypertension (AH), Type 2 diabetes mellitus (DM-2), and visceral obesity (VO), taking into account antihypertensive effects and dynamics of endothelial dysfunction (ED) biochemical markers. Material and methods. In total, 27 women with DM-2, Stage I AH, and VO, not receiving any regular antihypertensive treatment before, were examined. Mean participants’ age was 52,0±5,5 years, mean duration of DM-2, AH, and VO - 3,23±1,0, 5,93±2,28, and 13,53±3,75 years, respectively. Anthropometry, 24-hour blood pressure monitoring (BPM), measurement of endotheline-1 (ET-1), stable NO metabolites (NOn), fasting and postprandial glucose, as well as glycated hemoglobin (%) levels were performed. Results. Rilmenidine therapy (1 mg/d) was associated with target BP level achievement in 77,8% of the patients, decrease in mean 24-hour, daytime and nighttime systolic BP (SBP) by 10,6%, 12,1% and 7%, respectively (р<0,001), and regression of “load” parameters. Circadian SBP index significantly increased (by 3,29 mm Hg; р<0,001), the percentage of patients with normal circadian rhythm («dippers») increased from 49,3% to 74,2%. Heart rate was significantly reduced, from 85,24±4,78 to 72,32±4,24 bpm (р<0,05). Rilmenidine and atorvastatin therapy was associated with reduction in the levels of total cholesterol (by 27%; p<0,05), low-density lipoprotein cholesterol (by 36%; p<0,01), and triglycerides (by 24%; p<0,05). BP decrease and lipid profile improvement were accompanied by decreased ET-1 activity (by 50%; р<0,05) and increased NOn concentration (by 9,7%; р<0,05). No negative effects on carbohydrate metabolism were registered during the follow-up period. Conclusion. The results obtained could be used as an additional argument supporting rilmenidine therapy for AH management in women with DM-2 and VO. |
| first_indexed | 2024-04-10T03:41:45Z |
| format | Article |
| id | doaj.art-849ce62c082f44348c5158ee0554d961 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:41:45Z |
| publishDate | 1970-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-849ce62c082f44348c5158ee0554d9612023-03-13T07:23:10Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-016815201282Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesityE. V. Eliseeva0O. V. Gaydarova1O. V. Borushnova2L. A. Shapkina3A. M. Morozova4ГОУ ВПО «Владивостокский государственный медицинский университет Росздрава», ВладивостокГОУ ВПО «Владивостокский государственный медицинский университет Росздрава», ВладивостокГОУ ВПО «Владивостокский государственный медицинский университет Росздрава», ВладивостокГОУ ВПО «Владивостокский государственный медицинский университет Росздрава», ВладивостокГОУ ВПО «Владивостокский государственный медицинский университет Росздрава», ВладивостокAim. To assess the effectiveness of a selective I1 imidazoline receptor agonist, rilmenidine, in women with Stage I arterial hypertension (AH), Type 2 diabetes mellitus (DM-2), and visceral obesity (VO), taking into account antihypertensive effects and dynamics of endothelial dysfunction (ED) biochemical markers. Material and methods. In total, 27 women with DM-2, Stage I AH, and VO, not receiving any regular antihypertensive treatment before, were examined. Mean participants’ age was 52,0±5,5 years, mean duration of DM-2, AH, and VO - 3,23±1,0, 5,93±2,28, and 13,53±3,75 years, respectively. Anthropometry, 24-hour blood pressure monitoring (BPM), measurement of endotheline-1 (ET-1), stable NO metabolites (NOn), fasting and postprandial glucose, as well as glycated hemoglobin (%) levels were performed. Results. Rilmenidine therapy (1 mg/d) was associated with target BP level achievement in 77,8% of the patients, decrease in mean 24-hour, daytime and nighttime systolic BP (SBP) by 10,6%, 12,1% and 7%, respectively (р<0,001), and regression of “load” parameters. Circadian SBP index significantly increased (by 3,29 mm Hg; р<0,001), the percentage of patients with normal circadian rhythm («dippers») increased from 49,3% to 74,2%. Heart rate was significantly reduced, from 85,24±4,78 to 72,32±4,24 bpm (р<0,05). Rilmenidine and atorvastatin therapy was associated with reduction in the levels of total cholesterol (by 27%; p<0,05), low-density lipoprotein cholesterol (by 36%; p<0,01), and triglycerides (by 24%; p<0,05). BP decrease and lipid profile improvement were accompanied by decreased ET-1 activity (by 50%; р<0,05) and increased NOn concentration (by 9,7%; р<0,05). No negative effects on carbohydrate metabolism were registered during the follow-up period. Conclusion. The results obtained could be used as an additional argument supporting rilmenidine therapy for AH management in women with DM-2 and VO.https://cardiovascular.elpub.ru/jour/article/view/1565сахарный диабет 2 типаартериальная гипертензиявисцеральное ожирениеэндотелиальная дисфункциярилменидин |
| spellingShingle | E. V. Eliseeva O. V. Gaydarova O. V. Borushnova L. A. Shapkina A. M. Morozova Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity Кардиоваскулярная терапия и профилактика сахарный диабет 2 типа артериальная гипертензия висцеральное ожирение эндотелиальная дисфункция рилменидин |
| title | Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity |
| title_full | Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity |
| title_fullStr | Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity |
| title_full_unstemmed | Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity |
| title_short | Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity |
| title_sort | rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension type 2 diabetes mellitus and visceral obesity |
| topic | сахарный диабет 2 типа артериальная гипертензия висцеральное ожирение эндотелиальная дисфункция рилменидин |
| url | https://cardiovascular.elpub.ru/jour/article/view/1565 |
| work_keys_str_mv | AT eveliseeva rilmenidinetherapypotentialinpharmaceuticalcorrectionofendothelialdysfunctionamongwomenwitharterialhypertensiontype2diabetesmellitusandvisceralobesity AT ovgaydarova rilmenidinetherapypotentialinpharmaceuticalcorrectionofendothelialdysfunctionamongwomenwitharterialhypertensiontype2diabetesmellitusandvisceralobesity AT ovborushnova rilmenidinetherapypotentialinpharmaceuticalcorrectionofendothelialdysfunctionamongwomenwitharterialhypertensiontype2diabetesmellitusandvisceralobesity AT lashapkina rilmenidinetherapypotentialinpharmaceuticalcorrectionofendothelialdysfunctionamongwomenwitharterialhypertensiontype2diabetesmellitusandvisceralobesity AT ammorozova rilmenidinetherapypotentialinpharmaceuticalcorrectionofendothelialdysfunctionamongwomenwitharterialhypertensiontype2diabetesmellitusandvisceralobesity |